BRISBANE, Calif. / Sep 20, 2023 / Business Wire / Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell & Genetic Medicine Summit, to be held from September 26-27, 2023 in New York City.
Sandy Macrae, Sangamo’s President and Chief Executive Officer is scheduled to present on Wednesday, September 27th at 11:00AM ET. A live webcast of the presentation will be available here and on the Company’s Investor Events webpage. A replay of the presentation will be available on the Sangamo Therapeutics website for 90 days after the event.
About Sangamo Therapeutics
Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter.
| Last Trade: | US$0.64 |
| Daily Change: | -0.0059 -0.91 |
| Daily Volume: | 5,028,538 |
| Market Cap: | US$192.790M |
September 04, 2025 August 07, 2025 June 24, 2025 May 12, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
